Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia
Assess the immunotherapy benefit of interleukin-2 in acute myelogenous leukemia treatment during lymphocyte recovery.
Acute Myelogenous Leukemia
DRUG: Interleukin-2
Event-free Survival, Event-free survival (EFS) = all patients; measured from the date of entry onto study until treatment failure, AML relapse, or death, 3 years
Upon lymphocyte recovery after myeloablative induction standard chemotherapy pulse Interleukin-2 administered